The number of medicines and vaccines containing a new active substance (NAS) approved in the EU hit a new high last year, with 55 products receiving a centralized marketing authorization, compared with 52 in 2021, which itself was a record number.
Orphan drug approvals also set a new benchmark in 2022, with 21 medicines for rare diseases accounting for more than...